April 9, 2018
Swiss drugmaker Novartis buys US-based gene therapy company for $8.7 billion
Novartis’s acquisition of the US-based Nasdaq-listed clinical stage gene therapy company AveXis for $218 per share, for total of 8.7…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
April 6, 2018
Encapsulated cell therapies for the potential treatment of type 1 diabetes from Lilly and Sigilon
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for the potential treatment of…
April 5, 2018
Nordic Nanovector’s CEO steps down
Nordic Nanovector’s Chief Executive Officer Luigi Costa will step down, and the company will search for a new CEO immediately,…
April 4, 2018
Phase 3 study in second-line liver cancer patients met overall survival endpoint
Eli Lilly has announced top-line results from its Phase 3 REACH-2 study of its second-line treatment for liver cancer CYRAMZA,…
April 3, 2018
Edinburgh-based pharmaceutical company Neurocentrx aims global market with new board members
Neurocentrx, an Edinburgh-based pharmaceutical company, has appointed Nigel Brooksby as Non-Executive Chairman and Dr. Tim Corn as Non-Executive Director as…
March 29, 2018
Shire reaches regulatory milestones for investigational hereditary angioedema (HAE) treatment Lanadelumab
European Medicines Agency (EMA) has validated Shire’s marketing authorization application (MAA) for its lanadelumab, which was also accepted by Health…
March 29, 2018
EMA to review Sanofi’s potential treatment for type 1 diabetes
The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for oral treatment sotagliflozin, developed in partnership with…
March 29, 2018
EMA accepts BioMarin’s Pegvaliase MAA for treatment of Phenylketonuria (PKU)
European Medicines Agency (EMA) has accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase for the treatment of…
March 28, 2018
Actinium to work with Astellas Pharma on its AWE Platform Technology
Actinium Pharmaceuticals and Astellas Pharma will work together to develop Actinium-225 Radio-Conjugates (ARCs) using Actinium Warhead Enabling (AWE) Platform Technology,…
March 28, 2018
First approved biosimilar from Biocon and Mylan’s joint portfolio in Europe
The European Commission has approved Mylan/Biocon’s co-developed biosimilar insulin glargine Semglee marketing authorization for people with diabetes after it got…